DK1337525T3 - Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol - Google Patents

Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol

Info

Publication number
DK1337525T3
DK1337525T3 DK01998545.6T DK01998545T DK1337525T3 DK 1337525 T3 DK1337525 T3 DK 1337525T3 DK 01998545 T DK01998545 T DK 01998545T DK 1337525 T3 DK1337525 T3 DK 1337525T3
Authority
DK
Denmark
Prior art keywords
lansoprazole
crystal
crystallizing
production method
present
Prior art date
Application number
DK01998545.6T
Other languages
English (en)
Inventor
Tadashi Urai
Hideo Hashimoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18838123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1337525(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of DK1337525T3 publication Critical patent/DK1337525T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK01998545.6T 2000-12-01 2001-11-30 Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol DK1337525T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000367757 2000-12-01
PCT/JP2001/010462 WO2002044167A1 (en) 2000-12-01 2001-11-30 Process for the crystallization of (r)- or (s)-lansoprazole

Publications (1)

Publication Number Publication Date
DK1337525T3 true DK1337525T3 (da) 2011-09-19

Family

ID=18838123

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01998545.6T DK1337525T3 (da) 2000-12-01 2001-11-30 Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol

Country Status (17)

Country Link
US (2) US7285668B2 (da)
EP (2) EP2345650A1 (da)
KR (3) KR100939948B1 (da)
CN (1) CN1254473C (da)
AT (1) ATE511508T1 (da)
AU (1) AU2002218506A1 (da)
CA (1) CA2436825C (da)
CY (1) CY1112347T1 (da)
DK (1) DK1337525T3 (da)
ES (1) ES2367419T3 (da)
HK (1) HK1054380B (da)
HU (1) HU229356B1 (da)
NO (1) NO326019B1 (da)
PL (3) PL214684B1 (da)
PT (1) PT1337525E (da)
TW (1) TWI290922B (da)
WO (1) WO2002044167A1 (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020027315A1 (en) * 2000-03-10 2002-03-07 Parker Gerard E. Low-firing temperature method for producing Al2O3 bodies having enhanced chemical resistance
CA2409044C (en) 2000-05-15 2013-02-19 Takeda Chemical Industries, Ltd. Improved recrystallization processes for obtaining anhydrous optically active lansoprazole
IL164153A0 (en) * 2002-03-27 2005-12-18 Teval Pharmaceutical Ind Ltd Lansoprazole polymorphs and processes for preparation thereof
WO2004035052A1 (ja) 2002-10-16 2004-04-29 Takeda Pharmaceutical Company Limited 安定な固形製剤
JPWO2004067526A1 (ja) * 2003-01-31 2006-05-18 帝人ファーマ株式会社 （２３Ｓ）−１α−ヒドロキシ−２７−ノル−２５−メチレンビタミンＤ３−２６，２３−ラクトンの結晶およびその製造方法
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MXPA06000529A (es) * 2003-07-18 2006-08-11 Santarus Inc Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para elaborarlas y utilizarlas.
EP1648417A4 (en) * 2003-07-18 2010-01-20 Santarus Inc PHARMACEUTICAL FORMULATION AND METHOD FOR THE TREATMENT OF GASTROINTESTINAL ACIDITY RELATED DISORDERS
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
EP1718303A4 (en) * 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
EP1681056A1 (en) 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Process for preparing lansoprazole
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
ZA200805646B (en) 2005-12-28 2009-12-30 Takeda Pharmaceutical Controlled release solid preparation
KR100758600B1 (ko) 2006-01-05 2007-09-13 주식회사 대웅제약 란소프라졸 결정형 ａ의 제조방법
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008081891A1 (ja) 2006-12-28 2008-07-10 Takeda Pharmaceutical Company Limited 口腔内崩壊性固形製剤
WO2008087665A2 (en) * 2007-01-18 2008-07-24 Matrix Laboratories Ltd Process for preparation of lansoprazole
KR101303813B1 (ko) 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
MY153062A (en) * 2007-10-12 2014-12-31 Takeda Pharmaceuticals Usa Inc Methods of treating gastrointestinal disorders independent of the intake of food
EP2222663A1 (en) * 2007-12-18 2010-09-01 Watson Pharma Private Limited A process for preparation of stable amorphous r-lansoprazole
PE20091680A1 (es) 2008-03-10 2009-11-16 Takeda Pharmaceutical Cristal de compuestos de bencimidazol
EP2303868A2 (en) * 2008-05-14 2011-04-06 Watson Pharma Private Limited Stable r(+)-lansoprazole amine salt and a process for preparing the same
US20100113527A1 (en) * 2008-09-30 2010-05-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
KR101321055B1 (ko) * 2008-11-14 2013-10-23 한미사이언스 주식회사 덱스란소프라졸의 신규 결정형 및 이를 포함하는 약학 조성물
IT1391776B1 (it) * 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
WO2010095144A2 (en) * 2009-02-04 2010-08-26 Msn Laboratories Limited Process for the preparation of proton pump inhibitors
IT1392813B1 (it) * 2009-02-06 2012-03-23 Dipharma Francis Srl Forme cristalline di dexlansoprazolo
US20110009637A1 (en) * 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011004387A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
IT1395118B1 (it) * 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
US20130197232A1 (en) 2010-01-29 2013-08-01 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
EP2552903A1 (en) 2010-03-31 2013-02-06 Ranbaxy Laboratories Limited Salts of dexlansoprazole and their preparation
AU2011234003B2 (en) * 2010-03-31 2013-09-19 Sun Pharmaceutical Industries Limited Process for the preparation of dexlansoprazole
US20130216617A1 (en) 2010-06-29 2013-08-22 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
EP2647381A4 (en) 2010-12-03 2015-12-23 Takeda Pharmaceutical MELTING TABLET
SG10201602311XA (en) 2010-12-27 2016-04-28 Takeda Pharmaceutical Orally disintegrating tablet
WO2012104805A1 (en) 2011-02-01 2012-08-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
US20140357870A1 (en) 2011-06-21 2014-12-04 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
CN102234265B (zh) * 2011-08-08 2013-11-20 天津市汉康医药生物技术有限公司 兰索拉唑化合物
TWI630002B (zh) 2011-11-30 2018-07-21 武田藥品工業股份有限公司 乾塗覆錠
CN104025155B (zh) 2011-12-29 2017-07-25 英特尔公司 可变深度压缩
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
WO2013179194A1 (en) 2012-05-31 2013-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline dexlansoprazole
MY184077A (en) 2013-05-21 2021-03-17 Takeda Pharmaceuticals Co Orally disintegrable tablet
CN103254174B (zh) * 2013-06-05 2014-06-11 湖北济生医药有限公司 一种兰索拉唑化合物及其药物组合物
JP6557946B2 (ja) 2013-06-20 2019-08-14 日本ポリプロ株式会社 プロピレン系ブロック共重合体
CN104958276A (zh) * 2015-07-30 2015-10-07 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物兰索拉唑组合物胶囊
CN104997739A (zh) * 2015-08-31 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化系统疾病的药物兰索拉唑组合物冻干粉针剂
CN105399728B (zh) * 2015-12-20 2017-11-28 寿光富康制药有限公司 一种适用于工业化生产的右兰索拉唑的处理方法
CN106279107A (zh) * 2016-08-10 2017-01-04 成都尚药科技有限公司 一种右旋兰索拉唑晶型的制备方法
CN106749182A (zh) * 2016-11-08 2017-05-31 山东裕欣药业有限公司 一种右旋兰索拉唑晶型化合物及其制备方法
IT201700050223A1 (it) 2017-05-09 2018-11-09 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
JPH1085502A (ja) * 1996-09-19 1998-04-07 Konica Corp 晶析方法
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
TR199901101T2 (xx) * 1996-11-22 1999-07-21 The Procter & Gamble Company Gastroenstentinal hastal�klar�n tedavisine y�nelik bizmut ve nsaid i�eren bile�imler.
JP2002501896A (ja) * 1998-01-30 2002-01-22 セプラコール， インク． Ｓ−ランソプラゾール組成物及び方法
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
JP4536905B2 (ja) * 1999-06-17 2010-09-01 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
ATE298334T1 (de) * 1999-06-30 2005-07-15 Takeda Pharmaceutical Kristalle von lansoprazole
JP2001039975A (ja) * 1999-07-26 2001-02-13 Eisai Co Ltd スルホキシド誘導体の結晶およびその製造法
AU6727700A (en) 1999-08-25 2001-03-19 Takeda Chemical Industries Ltd. Process for the preparation of optically active sulfoxide derivatives
US6982275B2 (en) 2000-04-28 2006-01-03 Takeda Pharmaceutical Company Limited Process for producing optically active sulfoxide derivative
CA2409044C (en) 2000-05-15 2013-02-19 Takeda Chemical Industries, Ltd. Improved recrystallization processes for obtaining anhydrous optically active lansoprazole
CN1117747C (zh) * 2000-06-19 2003-08-13 中国科学院成都有机化学研究所 光学纯兰索拉唑的制备方法

Also Published As

Publication number Publication date
US20080306118A1 (en) 2008-12-11
KR100939948B1 (ko) 2010-02-04
PL214684B1 (pl) 2013-09-30
ES2367419T3 (es) 2011-11-03
HUP0400781A3 (en) 2010-03-29
CA2436825A1 (en) 2002-06-06
CN1478086A (zh) 2004-02-25
PL362801A1 (en) 2004-11-02
PT1337525E (pt) 2011-09-01
US7285668B2 (en) 2007-10-23
EP1337525B1 (en) 2011-06-01
US20040049045A1 (en) 2004-03-11
EP2345650A1 (en) 2011-07-20
AU2002218506A1 (en) 2002-06-11
CA2436825C (en) 2011-01-18
CN1254473C (zh) 2006-05-03
PL399787A1 (pl) 2012-11-05
HU229356B1 (en) 2013-11-28
EP1337525B8 (en) 2011-10-05
ATE511508T1 (de) 2011-06-15
PL409463A1 (pl) 2016-02-15
NO20032437D0 (no) 2003-05-28
CY1112347T1 (el) 2015-12-09
NO20032437L (no) 2003-07-17
KR20100002278A (ko) 2010-01-06
TWI290922B (en) 2007-12-11
HUP0400781A2 (hu) 2004-07-28
KR100887912B1 (ko) 2009-03-12
KR20030060967A (ko) 2003-07-16
EP1337525A1 (en) 2003-08-27
HK1054380A1 (da) 2003-11-28
KR20090003348A (ko) 2009-01-09
WO2002044167A1 (en) 2002-06-06
NO326019B1 (no) 2008-09-01
HK1054380B (zh) 2012-01-27

Similar Documents

Publication Publication Date Title
DK1337525T3 (da) Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol
DK0573848T3 (da) Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
DK0506866T3 (da) Fremgangsmåde til krystallisation af enzymer
DE60105113D1 (de) Verfahren zur Herstellung von einem Kristallepoxid
DE60235089D1 (de) Verfahren zur stabilisierung von reduziertem coenzym q10 und verfahren zur sauren kristallisation
NO20005660L (no) Nye mellomprodukter og fremgangsmåter for fremstilling av optisk aktive oktansyrederivater
DE60316791D1 (de) Verfahren zur aufreinigung von lanzoprazol
DE502005004950D1 (de) Verfahren zur herstellung einer lösung von reinem triethylendiamin (teda)
HUP0302530A2 (hu) Eljárás 2-nitro-4-metilszulfonil-benzoesav tisztítására
ATE272436T1 (de) Mikrofiltration unter verwendung von aktivkohle
BR9913720A (pt) Processo de purificação por cristalização ourecristalização de ácidos carboxìlicos
ATE115547T1 (de) Verfahren zur reinigung von tetraacetylethylendiamin (taed).
DK0782996T3 (da) Fremgangsmåde til fremstilling af N-biphenylmethylthiadiazolinderivat eller salt deraf og mellemprodukt til fremstilling af
DK1307101T3 (da) Fremgangsmåde til fremstilling af et biocidtkoncentrat
DE60019723D1 (de) Eine methode zur herstellung von verbindungen der formel 1 und derivaten
TH57580B (th) วิธีการผลิตผลึก
DE60233541D1 (de) Verfahren zur Reinigung von 5'-geschützten 2'-Deoxypurin Nukleosiden
ATE307140T1 (de) Kristallisierung von alpha-l-aspartyl-l- phenylalaninmethylester aus übersättigten lösungen
BR0307880A (pt) Método para purificar um composto de nióbio e/ou um composto de tântalo altamente puro
DK1462439T3 (da) Hidtil ukendte stabile krystaller af substitueret phenylpropionsyrederivat og fremgangsmåder til fremstilling af den samme
ATE264314T1 (de) Benzoxazol-derivate, verfahren zu ihrer herstellung und herbizide
DK1567516T3 (da) Fremgangsmåde til rensning af liponsyre
DE60201145D1 (de) Verfahren zur Reinigung von 5'-geschützten Thymidinen
DK0473435T3 (da) Mono-N,N-dimethyl-4-aminopyridinium-sn-glycerol-3-phosphat, fremstilling og anvendelse deraf til fremstilling af phosphatidsyrer
DE60123213D1 (de) Alkalimetallsalz von thiazolidin-2,4-dion-derivaten